Pain Therapeutics, Inc. (NASDAQ:PTIE) – Research analysts at Gabelli issued their FY2021 earnings per share estimates for Pain Therapeutics in a research note issued on Thursday, according to Zacks Investment Research. Gabelli analyst K. Kedra anticipates that the biopharmaceutical company will earn ($0.35) per share for the year.
Pain Therapeutics (NASDAQ:PTIE) traded down 1.3384% during mid-day trading on Friday, reaching $0.7814. The company’s stock had a trading volume of 249,263 shares. Pain Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.00. The company’s market cap is $36.05 million. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $0.67.
A number of large investors have recently bought and sold shares of PTIE. Gabelli Funds LLC boosted its stake in Pain Therapeutics by 9.4% in the fourth quarter. Gabelli Funds LLC now owns 175,000 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 15,000 shares during the period. BVF Inc. IL raised its position in Pain Therapeutics by 6.0% in the third quarter. BVF Inc. IL now owns 2,278,552 shares of the biopharmaceutical company’s stock valued at $2,278,000 after buying an additional 128,639 shares in the last quarter. Spark Investment Management LLC purchased a new position in Pain Therapeutics during the third quarter valued at approximately $119,000. Finally, Acadian Asset Management LLC raised its position in Pain Therapeutics by 26.3% in the third quarter. Acadian Asset Management LLC now owns 443,430 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 92,358 shares in the last quarter. 44.34% of the stock is owned by institutional investors.
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Get a free copy of the Zacks research report on Pain Therapeutics (PTIE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com